Litteratur
1. Strandberg K, Beerman B, Lönnerholm G (red). Phar–
macological Treatment of Venous Thromboembo–
lism. Uppsala: Drug Information Committee, Swe–
dish National Board of Health and Welfare,
1987:1-190.
2.Greaves M, Preston FE. The hypercoagulable state in
clinical practice. Brit J Haemato/1991;79:149-51 .
3.Lowe GDO, Greer iA, Cooke TG, Evans MJ, Forbes
CD, Mollan RAB et al. Thromboembolic Risk Factors
(THRIFT) Consensus Group: Risk of and prophylaxis
for venous thromboembolism in hospital patients.
Brit Med J 1992;305:567-74.
4.Goldhaber SZ, Morpurgo M . Diagnosis, treatment,
and prevention of pulmonary embolism. Report of
the WHO/International Society and Federation of
Cardiology Task Force. JAMA 1992;268:1727-33.
5.Wiman B, Hamsten A . The fibrinelytic enzyme sys–
tem and its role in the etiology of thromboembolic
disease. Sem Thrombosis Hemostasis 1990;16:
207-16.
6.Tengborn L, Larsson SA, Hedner U, Nilsson IM. Coa–
gulation studies in children and young adults with
cerebral ischemic episodes. Acta Neuro! Scand
1981;63:351 -61.
7.Tengborn L. Lupus antikoagulans - riskfaktor för
trombos. Läkartidningen 1987;84:15-6.
8.Pope JM, Canny CLB, Bell DA . Cerebral ischemic
events associated with endocarditis, retinal vaseular
disease, and lupus anticoagulant. Am J Med
1991;90:299-309.
9.Asherson RA, Cervera R. The antiphospholipid syn–
drome: a syndrome in evolution. Ann Rheum Dis
1992;51:147-50.
10. Soscia PN, Romain PL. Antiphopholipid antibodies:
Klinisk kemi i Norden 4, /992
•
is there a role in cardiac valvular disease and its
thromboembolic complications? Cardiology 1992;
80:1-6.
11. Out HJ, Bruinse HW, Derksen RHWM . Anti –
phospholipid antibodies and pregnancy loss. Hum
Reprad 1991:6:889-97.
12. Lindstedt G, Lundberg P-A, Westberg G, Kaijser B.
SLE nephritis with positive tests for antibodies aga–
inst native DNA but negagive tests for antinuclear
antibodies. Lancet 1977;ii:135.
13. Unander AM, Norberg R, Hahn L, Artors L. Anti–
cardiolipin antibodies and complement in 99 women
with habitual abortion. Am J Obstet Gynecol
1987;156:114-21 .
14. Socialstyrelsens läkemedelsavdelning. Rekommen–
dationer om profylax och terapi vid venös trombo–
embolism 1987:12:133-44.
15. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA .
Anti -phospholipid antibodies are directed against a
complex antigenthat includes a lipid-binding inhibi–
tor of coagulation: P2 -glycoprotein l (apolipoprotein
H). Proc Natt Acad Sci USA 1992;87:4120-4 .
16. Galli M, Comfurius P, Maasen C, Hemker HC, de
Baets MH, van Breda-Vriesman PJC et al. Anticar–
diolipin antibodies (ACAI directed not to cardiolipin
but to plasma cofactor. Lancet 1990;335:1544-7.
17. McNeil HP, Krilis SA. Antiphospholipid antibodies.
Aust NZ J Med 1991;21 :463-75.
18. McNeil HP, Chesterman CN, Krilis SA. lmmunology
and clinical importance of antiphospholipid anti–
bodies. Adv /mmuno/1991 ;49:193-280.
19. Dahlbäck B, Nilsson l M, Frohm B. Inhibition of plate–
let prothrombinase activity by a lupus anticoa–
gulant. 8/ood 1983;62:218-25.
25
